Draft Genome Sequences of Sixteen Fluoroquinolone-Resistant Extraintestinal *Escherichia coli* Isolates from Human Patients

Khulud Alotaibi,*, Ashraf A. Khan, Bernard Marasa, Saeed A. Khan, James Johnson, Brian Johnston, Kidon Sung, Mohamed Nawaz

*U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas, USA
†Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
‡Minneapolis Veteran Administration Healthcare System, Minneapolis, Minnesota, USA

**ABSTRACT** We report here the draft genome sequences of 16 fluoroquinolone-resistant extraintestinal *Escherichia coli* isolates from human patients. These isolates had high MICs (32 to 256 μg/mL) for ciprofloxacin and contained point mutations in the quinolone resistance-determining region (QRDR) of both *gyrA* and *parC* that confer resistance to fluoroquinolone. The whole-genome sequence data provide a better understanding of the fluoroquinolone resistance mechanisms in these isolates and would be beneficial in source tracking these pathogens during pandemic outbreaks.

Urinary tract infection (UTI) is an extremely common bacterial infection of the bladder and/or kidney. It affects more than a billion women worldwide (1) and about 8 million women in the United States, resulting in approximately 100,000 hospitalizations (1–3). Untreated UTI can lead to septic shock and death and contributes to preterm labor, agitation, or delirium in the elderly (1). The incidence of UTI increases with age and sexual activity. UTI is commonly treated with antibiotics such as ciprofloxacin, trimethoprim-sulfamethoxazole, cephalosporins, and nitrofurans (3–5).

Most community-acquired UTI episodes (80%) are caused by *Escherichia coli*, and most UTI-causing *E. coli* strains are uropathogenic *E. coli* (UPEC). UPEC strains have distinctive virulence capabilities that distinguish them from diarrheagenic and commensal *E. coli* and allow the UPEC strains to colonize, invade, injure, and trigger inflammation at extraintestinal sites, thereby producing disease.

Most UPEC strains belong to *E. coli* phylogenetic group B2 or D and are often clonal; the leading sequence types (STs) isolated worldwide are ST69, ST73, ST95, and ST131 (5–7). These clones are a major contributor to hospital- and community-acquired UTIs and bloodstream infections and are multidrug resistant (MDR), including having resistance to fluoroquinolones (5–7), and are a major public health concern (5–10).

The *E. coli* strains used in this study were isolated by streaking urine samples on MacConkey agar plates incubated at 37°C. These strains were isolated by the Department of Veteran’s Affairs (VA), Minneapolis, Minnesota, after approval from their institutional review board (IRB). Presumptive positive colonies of *E. coli* were identified by the Vitek GNI+ card with VTK-RO7.01 software (bioMérieux Vitek, Hazelwood, MO). Sixteen *E. coli* strains were resistant to fluoroquinolone (FQ). All 16 FQ-resistant isolates had MICs of 128 to 256 μg/mL for nalidixic acid and 32 to 256 μg/mL for ciprofloxacin. The genome sequences of these isolates will be useful for further understanding the mechanism of FQ resistance, virulence properties, and source tracking of these isolates during pandemic outbreaks.

Genomic DNA was extracted from overnight cultures on MacConkey agar plates using the DNeasy blood and tissue kit (Qiagen, Valencia, CA). DNA libraries were...
TABLE 1 Summary of genome sequence analysis of extraintestinal Escherichia coli isolates from human patients

| Isolate                  | \( N_c \) (bp) | No. of contigs | Total no. of reads | Genome length (bp) | Genome coverage (\( X \)) | No. of CDSs\(^a\) | G+C content (%) | SRA accession no. | GenBank accession no. |
|-------------------------|----------------|---------------|-------------------|-------------------|---------------------------|------------------|-----------------|------------------|----------------------|
| Escherichia coli MVAST4410 | 73,614         | 181           | 5,238,611         | 5,239,854         | 50                        | 4,988            | 50.55           | SRA9748648        | VAEME000000000000    |
| Escherichia coli MVAST2986 | 191,314        | 107           | 5,093,752         | 5,095,001         | 50                        | 4,904            | 50.73           | SRA9748649        | VAEME000000000000    |
| Escherichia coli MVAST3079 | 44,133         | 280           | 5,083,391         | 5,083,391         | 50                        | 4,930            | 50.86           | SRA9748656        | VAEME000000000000    |
| Escherichia coli MVAST3385 | 190,966        | 124           | 5,284,823         | 5,282,826         | 50                        | 5,146            | 50.88           | SRA9748657        | VAEME000000000000    |
| Escherichia coli MVAST3887 | 55,163         | 242           | 5,282,959         | 5,279,786         | 50                        | 5,063            | 50.58           | SRA9748658        | VAEME000000000000    |
| Escherichia coli MVAST2284 | 158,975        | 120           | 5,267,684         | 5,267,772         | 50                        | 5,130            | 50.67           | SRA9748659        | VAEME000000000000    |
| Escherichia coli MVAST4331 | 191,083        | 110           | 5,093,752         | 5,095,354         | 50                        | 4,930            | 50.76           | SRA9748660        | VAEME000000000000    |
| Escherichia coli MVAST2842 | 110,606        | 175           | 5,166,958         | 5,166,958         | 50                        | 5,024            | 50.82           | SRA9748661        | VAEME000000000000    |
| Escherichia coli MVAST2624 | 74,671         | 196           | 5,111,376         | 5,117,732         | 50                        | 4,966            | 50.80           | SRA9748662        | VAEME000000000000    |
| Escherichia coli MVAST3604 | 190,899        | 86            | 5,242,655         | 5,242,655         | 50                        | 5,062            | 50.68           | SRA9748663        | VAEME000000000000    |
| Escherichia coli MVAST4169 | 103,745        | 142           | 5,022,955         | 5,022,955         | 50                        | 4,823            | 50.62           | SRA9748650        | VAEME000000000000    |
| Escherichia coli MVAST2250 | 130,178        | 114           | 5,136,438         | 5,136,438         | 50                        | 4,854            | 50.54           | SRA9748651        | VAEME000000000000    |
| Escherichia coli MVAST3636 | 105,677        | 140           | 5,141,629         | 5,141,629         | 50                        | 4,949            | 50.62           | SRA9748652        | VAEME000000000000    |
| Escherichia coli MVAST2316 | 64,078         | 212           | 5,029,007         | 5,029,007         | 50                        | 4,861            | 50.79           | SRA9748653        | VAEME000000000000    |
| Escherichia coli MVAST3575 | 147,709        | 137           | 5,414,888         | 5,414,888         | 50                        | 5,312            | 50.60           | SRA9748654        | VAEME000000000000    |
| Escherichia coli MVAST4715 | 140,083        | 130           | 5,062,858         | 5,062,858         | 50                        | 4,869            | 50.59           | SRA9748655        | VAEME000000000000    |

\( ^a \)CDS, coding DNA sequence.

constructed by using the Nextera XT library prep kit (Illumina). The whole-genome sequence was performed using an Illumina MiSeq platform (Illumina, San Diego, CA) with 2 × 251-bp paired-end reads. Trimming and assembly were performed by using the CLC Genomics Workbench 21.0.4 (Qiagen).

Draft genomes were annotated initially using the Pathosystems Resources Integration Center (PATRIC) software version 3.6.12, and the data were submitted to the NCBI for final annotation to the Prokaryotic Genome Annotation Pipeline (PGAP) (11) under the accession numbers shown in Table 1. Default parameters were used for all software unless otherwise specified. The average G+C content of these strains was estimated to be approximately 50.69% as estimated by the PATRIC database, which was annotated using default parameters. Table 1 shows the number of contigs, sequence assembly size, coding sequences, and functional coding sequences for the respective strains.

Data availability. SRA submissions of FASTQ files and the draft genome sequences for these 16 UPEC strains have been deposited at DDBJ/ENA/GenBank under accession numbers given in Table 1 (BioProject accession number PRJNA669151). ACKNOWLEDGMENTS

We thank Carl E. Cerniglia, J.B. Sutherland, Steve Foley, and Huizhong Chen for critical review of the manuscript and Javier Revollo for help in DNA extraction.

This work was supported by the National Center for Toxicological Research, U.S. Food and Drug Administration. The manuscript reflects the views of the authors and does not necessarily reflect those of the United States Food and Drug Administration. Any mention of the commercial products is for clarification only and is not intended as approval or recommendation.

REFERENCES

1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infection: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269–284. https://doi.org/10.1038/nrmicro3432.
2. Dielubanza EJ, Schaeffer AJ. 2011. Urinary tract infections in women. Med Clin North Am 95:27–41. https://doi.org/10.1016/j.mcn.2010.08.023.
3. Barber AE, Norton JP, Spivak AM, Mulvey MA. 2013. Urinary tract infection: current and emerging management strategies. Clin Infect Dis 57:719–724. https://doi.org/10.1093/cid/cit2284.
4. Brown P, Ki M, Foxman B. 2005. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 23:1123–1142. https://doi.org/10.2165/00019053-200523110-00005.
5. Peirano G, Pitout JD. 2010. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: worldwide emergence of clone ST131O25:H4. Int J Antimicrob Agents 35:316–321. https://doi.org/10.1016/j.ijantimicag.2009.11.003.
6. Pitout JDD, DevInney R. 2017. Escherichia coli ST131: a multidrug-resistant clone primed for global domination. F1000Res 6:195. https://doi.org/10.12688/f1000research.10609.1.
7. Banerjee R, Johnson JR. 2014. A new clone sweeps clean: the enigmatic Escherichia coli MVAST4715. J Bacteriol 196:280–284. https://doi.org/10.1128/JB.01852-14.
8. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66:1–14. https://doi.org/10.1093/jac/dkq415.

9. Riley LW. 2014. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin Microbiol Infect 20:380–390. https://doi.org/10.1111/1469-0691.12646.

10. Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. Escherichia coli sequence type 131, an intriguing clonal group. Clin Microbiol Rev 27:543–574. https://doi.org/10.1128/CMR.00125-13.

11. Angiuoli SV, Gussman A, Klimke W, Cochrane G, Field D, Garrity G, Kodira CD, Kyrpides N, Madupu R, Markowitz V, Tatusova T, Thomson N, White O. 2008. Toward an online repository of standard operating procedures (SOPS) for (meta) genomic annotation. OMICS 12:137–141. https://doi.org/10.1089/omi.2008.0017.